On Tuesday, MedImmune revealed that its sales of the inhaled influenza vaccine FluMist have been much lower than expected, and that sales for the entire flu season will be less than predicted. The company had expected to sell between 4 million and 5 million doses of the vaccine for the 2003-2004 winter, but it has only sold 400,000 doses so far and does not expect to see a strong uptick in interest as the flu season moves along. MedImmune said that the poor sales could be attributed to the product's high price, its limited availability to patients, and a later commercial introduction than planned.